ENGASE

Cytosolic endo-beta-N-acetylglucosaminidase · Q8NFI3 · ENGASE on Sugi Atlas →

4,934 patent compounds predicted against ENGASE, 2,634 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL106666	0.63	3/20
SCHEMBL1307379	0.63	3/20
SCHEMBL6600434	0.62	3/20
SCHEMBL6600439	0.62	3/20
SCHEMBL1269347	0.61	3/20
SCHEMBL1457476	0.61	3/20
SCHEMBL1457477	0.61	3/20
Lansoprazole (SCHEMBL22365)	0.61	3/20
Lansoprazole (SCHEMBL22366)	0.61	3/20
Rabeprazole (SCHEMBL23336)	0.61	3/20
Rabeprazole (SCHEMBL23337)	0.61	3/20
Dexlansoprazole (SCHEMBL44975)	0.61	3/20
Lansoprazole (SCHEMBL1559598)	0.61	3/20
Dexrabeprazole (SCHEMBL4946138)	0.61	3/20
SCHEMBL2364997	0.60	3/20
SCHEMBL5414007	0.60	3/20
Rabeprazole (SCHEMBL140495)	0.60	3/20
Rabeprazole (SCHEMBL491358)	0.60	3/20
Rabeprazole (SCHEMBL491362)	0.60	3/20
Lansoprazole (SCHEMBL1067267)	0.60	3/20

Clinical trials — most relevant to ENGASE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease	PHASE4	COMPLETED
High Dose or High Dose Frequency Study of Alglucosidase Alfa	PHASE4	COMPLETED
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD	PHASE4	RECRUITING
Growth and Development Study of Alglucosidase Alfa	PHASE4	COMPLETED
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)	PHASE3	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients	PHASE2	ENROLLING_BY_INVITATION
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old	PHASE2	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia	PHASE1	WITHDRAWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease	nan	APPROVED_FOR_MARKETING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity	nan	COMPLETED
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients	nan	COMPLETED
Chitinases and Transforming Growth Factor Beta (TGFB) in Human Asthma	nan	COMPLETED
The Natural History of Sialidosis Type I	nan	RECRUITING
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Exploration of Immunity in Gaucher Disease	nan	COMPLETED
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)	nan	ACTIVE_NOT_RECRUITING
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ENGASE binder may also engage these)

Protein	Name	Similarity
Q8BX80	—	1.000	Q8BX80 →
P0C7A1	—	0.999	P0C7A1 →
Q3SYT1	—	0.993	Q3SYT1 →
O75064	—	0.992	O75064 →
D3ZEY4	—	0.992	D3ZEY4 →
Q9ESK3	—	0.990	Q9ESK3 →
A1L251	—	0.990	A1L251 →
Q6P5E8	—	0.989	Q6P5E8 →
Q9H6W3	—	0.989	Q9H6W3 →
Q5NCQ5	—	0.989	Q5NCQ5 →
Q9BZG8	—	0.989	Q9BZG8 →
E9QAM5	—	0.989	E9QAM5 →
Q6ZSI9	—	0.989	Q6ZSI9 →
P48760	—	0.988	P48760 →
P70671	—	0.988	P70671 →
JAK3	Tyrosine-protein kinase JAK3	0.988	landscape →
Q68DD2	—	0.988	Q68DD2 →
A6H751	—	0.988	A6H751 →
Q9Y4C4	—	0.988	Q9Y4C4 →
Q8BHW9	—	0.988	Q8BHW9 →
A0A8C2MDK8	—	0.988	A0A8C2MDK8 →
P23249	—	0.988	P23249 →
SMOX	Spermine oxidase	0.987	landscape →
Q8C9A2	—	0.987	Q8C9A2 →
IL4I1	L-amino-acid oxidase	0.987	landscape →
Q9HC96	—	0.987	Q9HC96 →
TYK2	Non-receptor tyrosine-protein kinase TYK2	0.987	landscape →
Q9R117	—	0.987	Q9R117 →
A7YY46	—	0.987	A7YY46 →
Q99J39	—	0.986	Q99J39 →